Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Pbo-Controlled, Study of EDP-494 to Evaluate the Safety and PK of SAD/FE in Healthy Subjects and MAD in Healthy and in Subjects With CHC Infection (POC).

Next Previous
Trial Profile

A Randomized, Double-Blind, Pbo-Controlled, Study of EDP-494 to Evaluate the Safety and PK of SAD/FE in Healthy Subjects and MAD in Healthy and in Subjects With CHC Infection (POC).

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 21 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EDP 494 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Proof of concept
  • Sponsors Enanta Pharmaceuticals

Most Recent Events

  • 06 Jan 2017 Status changed from recruiting to discontinued, as according to Enanta Pharmaceuticals media release the company has decided to stop further development of EDP-494 and to focus its efforts on its wholly-owned programs in NASH/PBC, RSV and HBV.
  • 03 Oct 2016 According to Enanta Pharmaceuticals media release, data will be presented at Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Nov 2016.
  • 04 Aug 2016 Planned End Date changed from 1 Sep 2016 to 1 Dec 2016.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top